Boehringer Ingelheim Venture Fund related stories
All articles and analysis
Bodyport amasses $11.2m Series ABodyport, a digital health company focused on the detection and management of heart disease, has secured $11.2 million in Series A funding.
- Swiss biotech firm T3 Pharmaceuticals lands funding
T3 Pharmaceuticals AG, a Swiss biotech company, has raised over 25 million CHF.
Etherna attracts Series BEtherna, a Belgian developer of immunotherapies for the treatment of cancer and infectious diseases, has secured 34 million euros in Series B funding.
Wellth nabs $10m Series AWellth, a health tech company, has raised $10 million in Series A funding.
- Actym Therapeutics rakes in $34m Series A
Berkeley, California-based Actym Therapeutics, an immuno-oncology company, has closed $34 million in Series A financing.
- Rgenta Therapeutics scores $20m seed
Cambridge, Massachusetts-based Rgenta Therapeutics, a developer of RNA-targeting medicines, has secured $20 million in seed funding.
- Swiss Biotech NBE Therapetics procures $22 mln Series C
NBE-Therapeutics AG, a Swiss biotech firm, has raised $22 million in Series C financing.
- Eyevensys secures $30 mln Series B
Eyevensys, a Paris-based developer of non-viral gene therapies for retinal and other ophthalmic diseases, has raised $30 million in Series B financing.
- Metabomed lands $12.5 mln
Metabomed, a cancer metabolism company, has secured $12.5 million in funding.
Abalos Therapeutics grabs Series AAbalos Therapeutics, a German cancer drug developer, has raised 12 million euros in Series A financing. Boehringer Ingelheim Venture Fund and Gruenderfonds Ruhr led the round.